Rapamycin forms a high-affinity complex with its cellular receptor FKBP12, which is overexpressed in lupus T cells, thereby blocking mTOR activation to improved disease activity in SLE patients (60, 61). This evidence concerns the gene FKBP1A and systemic lupus erythematosus.